在STRONG-HF试验中使用指南导向的医疗疗法
Xiang Zhang1, Beth Davison2,3,4, Marianna Adamo5
1Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada (X.Z., J.A.E.).
Circulation. Heart failure
|July 3, 2025
概括
一个新的GDMT强度得分有效地衡量了心力衰竭药物的使用,并与改善的临床结果有关. 这种标准化的方法提供了超越传统试验方法的全面评估.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 在心力衰竭 (HF) 试验中评估药物变化是复杂的,可能不完全代表患者的护理.
- 需要一个全面和标准化的方法来评估指南导向医学疗法 (GDMT) 在高频率.
- STRONG-HF试验为评估GDMT强度及其与临床结果的关联提供了一个平台.
研究的目的:
- 评估GDMT强度得分对评估心力衰竭患者药物使用的有用性.
- 检查STRONG-HF试验中GDMT强度得分和临床结果之间的关联.
- 为了比较常规护理和高强度护理策略之间的GDMT坚持和强度.
主要方法:
- 利用了STRONG-HF试验的数据,包括基线和后续评估.
- 应用GDMT强度得分来评估药物使用和药物坚持 (基本,指示纠正,剂量纠正).
- 与临床结果相关的GDMT强度得分,干预后长达180天.
主要成果:
- 高强度护理显著增加了三重治疗的指示-纠正和剂量-纠正的使用,与90天的通常护理相比 (P<0.001).
- 90天后,高强度治疗组中的88.4%的患者获得了GDMT强度得分>7,而常规治疗组的14.3% (P<0.0001).
- 基线和90天的GDMT强度得分与180天后改善的临床结果相关.
结论:
- GDMT强度得分提供了在心力衰竭中药物使用的标准化和全面的衡量标准.
- 这一分数与临床结果有显著的关联,突出了其预后价值.
- 在未来的心力衰竭研究中,GDMT强度得分应该被视为潜在的试验终点.
更多相关视频
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
11.8K
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.6K
相关概念视频
01:30Heart Failure V: Medical Management
33
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
33
01:22Heart Failure VI: Adjunct Therapies
38
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
38
01:21Rheumatic Heart Disease III: Medical Management
36
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
36
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524
01:26Mitral Stenosis III: Medical Management
28
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
28
01:26Heart Failure Drugs: Inotropic Agents
743
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
743